Insights
Search Results
Client Highlights
9.01.26
Firm Advises PMV Pharmaceuticals on Oversubscribed $50 Million Public Offering
On August 31, 2026, PMV Pharmaceuticals, a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced the pricing of an underwritten public offering consisting of 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, as well as accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The combined public offering price of each share of common stock and accompanying warrant is $1.21. The gross proceeds from the offering, before deducting underwriting discounts, commissions, offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million. Wilson Sonsini Goodrich & Rosati advised PMV Pharma on the transaction.
Client Highlights
8.18.26
Wilson Sonsini Advises InduPro on $77 Million Series B Financing
On August 12, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a $77 million Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Case Studies
8.14.26
How Wilson Sonsini Helped Soleno Therapeutics Position Itself as an Attractive Acquisition Target
Soleno Therapeutics, a Neurocrine Biosciences company, focuses on the treatment of rare diseases by identifying, developing, and commercializing novel therapeutics. Its lead commercial program addresses Prader-Willi syndrome (PWS), which occurs in approximately one in every 15,000 live births. One of the common symptoms of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense, persistent sensation of hunger.
Client Highlights
8.13.26
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
Client Highlights
8.11.26
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
8.11.26
Firm Advises Expedition Therapeutics on Patent Matters Related to $115 Million Series B
On August 5, 2026, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati is patent counsel to Expedition and advises the company on all patent matters, including those related to this transaction.
News Articles
8.04.26
San Diego Business Journal Names Nellie Brutocao Among 2026 "Leaders of Influence in Technology"
On August 3, 2026, Wilson Sonsini partner Nellie Brutocao was honored among the 2026 “Leaders of Influence in Technology” in San Diego Business Journal’s special supplement.
Client Highlights
8.03.26
Wilson Sonsini Advises Firefly Bio on $1 Billion Acquisition by Johnson & Johnson
On July 29, 2026, Johnson & Johnson announced the completion of its acquisition of Firefly Bio, a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances the company’s ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers. Wilson Sonsini Goodrich & Rosati advised Firefly Bio on the transaction.
Client Highlights
7.27.26
Wilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC
On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.
Client Highlights
7.21.26
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.